GLYSET (miglitol) by Pfizer is alpha glucosidase inhibitors [moa]. First approved in 1996.
Drug data last refreshed 4h ago · AI intelligence enriched 6d ago
GLYSET (miglitol) is an oral small-molecule alpha-glucosidase inhibitor approved in 1996 for type 2 diabetes management. It works by slowing carbohydrate digestion and glucose absorption in the small intestine, reducing postprandial blood glucose spikes. The drug is indicated as monotherapy or adjunctive therapy in patients with type 2 diabetes.
LOE-approaching lifecycle with moderate competitive pressure (30) indicates a mature, declining asset with reduced team expansion opportunities.
alpha Glucosidase Inhibitors
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Study to Assess Drug-Drug Interaction Between ASP1941 and Miglitol
Effects of Miglitol on Daily Plasma Glucose in type2 Diabetes Treated With Insulin
Open Trial of Miglitol in Type 1 Diabetic Patients With Insulin Treatment
Open Trial of Miglitol in Type 2 Diabetic Patients Treated With Biguanide
Double-Blind Trial of Miglitol in Type 2 Diabetic Patients With Insulin Treatment
Worked on GLYSET at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on GLYSET offers limited career growth due to its LOE-approaching status and mature lifecycle. Roles are primarily defensive (protecting market share, managing generics) rather than expansionary, making this asset less attractive for ambitious career progression.